DNA Script is a company focused on revolutionizing DNA writing with enzymes, particularly through the development of the SYNTAX System, the world’s first DNA printer powered by enzymatic technology. The company values excellence, transparency, and benevolence in its operations.

DNA Script

DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.

Hedonova

Sofinnova Partners

Kurma Partners

Illumina Ventures

Agilent Technologies

Danaher Life Science

Bpifrance

Casdin Capital

EQT life science

M Ventures

Baillie Gifford

eureKARE

Fidelity Management and Research Company

Catalio Capital Management

Coatue

Columbia Threadneedle Investments

HealthCor

HealthCor Partners

Irving Investors

An international group, including researchers at the Wyss Institute at Harvard University for Biologically Inspired Engineering, Dana-Farber Cancer Institute, and Boston Children's Hospital, extended DoriVac, a #DNA origami-based #vaccine platform, to infectious diseases.
 
By conjugating DoriVac with heptad repeat 2 (HR2) peptides, which play a role in fusing the viral and host cell membranes and are conserved across a host of viral species, the group observed that DoriVac induced neutralizing antibodies and CD4+ and CD8+ T-cell response in mice against SARS-CoV-2, HIV and Ebola. Immune response was also induced in a human lymph-node-on-chip model.
 
Taken together, the results suggest DoriVac, when conjugated to viral antigens, holds promise for inducing robust immune response and its flexible, modular nature may make it a good candidate system for responding to future global disease outbreaks.
#pandemic #immuneresponse #syntheticbiology
 
https://lnkd.in/epbFpdBR

Day 2 at PepTalk! Come stop by booth #714 if you're interested in learning more about enzymatic #DNA synthesis. Michael Delaney Sullivan, Melissa Gentz

A group at Dana-Farber Cancer Institute , along with researchers at the Broad Institute of MIT and Harvard,  and Massachusetts General Hospital Cancer Center, previously reported on a new technique called MAESTRO (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides) for assaying for minimal residual disease (#MRD) using #cfDNA. 
 
In a new study, this group expanded on MAESTRO with a new approach called MAESTRO-Pool. This technique pools MAESTRO probes from all patients assayed, which allowed the researchers to assay over 23,000 mutations in 9 melanoma patients over several cfDNA samples per patient. By pooling, the researchers were able to quantify MRD in matched patients as well as the rate of false positives in unmatched patients.
 
The assay showed a 10- to 100-fold improvement in sensitivity versus existing MRD tests and showed high specificity for detecting MRD.
#cancer #oligonucleotides #assaydevelopment
 
https://lnkd.in/g8z26pQG

We’ll be at PepTalk in San Diego from January 16th to 19th, and we hope to see you there! Come find Michael Delaney Sullivan and Melissa Gentz at Booth 714 to learn more about the SYNTAX System.

As we bring 2023 to a close, we reflect on this past year and the promise of benchtop enzymatic #DNA synthesis (EDS), and look back at a publication by a group at US Army which assessed benchtop #EDS for gene assembly applications. 
 
The study concluded that EDS-derived #oligonucleotides could be obtained in half the time of commercially-synthesized oligos, yielded functional gene product, and that EDS clearly reduced the waste stream compared to using traditional chemical synthesis methods for oligo production.
#oligo #DNAScript #genesynthesis #syntheticbiology
 
https://bit.ly/41GoPFD

COM:DNASCRIPT

DNA Script

Financials Not Available